17-beta-hydroxysteroid dehydrogenase type 7 (HSD17B7)

17-beta-hydroxysteroid dehydrogenase type 7 (HSD17B7) is a multifunctional enzyme of the short-chain dehydrogenase/reductase family, best known for its roles in *cholesterol biosynthesis* (as the mammalian ortholog of yeast Erg27p, catalyzing the reduction of zymosterone to zymosterol) and *steroid hormone metabolism* (notably the conversion of estrone to estradiol and inactivation of dihydrotestosterone)[2]. HSD17B7 is expressed in tissues with active cholesterol and steroid hormone metabolism, and its deficiency or dysregulation can lead to severe developmental malformation syndromes and may contribute to the progression of cancers such as breast carcinoma, due to its role in local estrogen synthesis and androgen catabolism[2][1]. If more structured or drug-centric information on approved interacting compounds is required, further pharmacological databases or recent reviews would be necessary, as current literature mostly discusses HSD17B7 as a candidate and mechanism but not as a direct drug target in clinical use.

Other names

3-keto-steroid reductaseDihydrotestosterone oxidoreductaseEstradiol 17-beta-dehydrogenase 7SDR37C1Short-chain dehydrogenase/reductase family 37C member 1PRAP17HSD717-beta-HSD 717beta hydroxysteroid dehydrogenase

Enzyme inhibition by small molecules to block conversion of precursor steroids or cholesterol intermediates. Downregulation or knockdown in cancer cells reduces estradiol levels and cell proliferation.